WO2023115123A1 - Intermédiaires cristallins - Google Patents

Intermédiaires cristallins Download PDF

Info

Publication number
WO2023115123A1
WO2023115123A1 PCT/AU2022/051546 AU2022051546W WO2023115123A1 WO 2023115123 A1 WO2023115123 A1 WO 2023115123A1 AU 2022051546 W AU2022051546 W AU 2022051546W WO 2023115123 A1 WO2023115123 A1 WO 2023115123A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
crystalline form
degrees
exhibits
Prior art date
Application number
PCT/AU2022/051546
Other languages
English (en)
Inventor
Luca Domenighini
Lorena FUMAGALLI
Andrea Gambini
Nicola Sardone
Original Assignee
QBiotics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021904153A external-priority patent/AU2021904153A0/en
Application filed by QBiotics Pty Ltd filed Critical QBiotics Pty Ltd
Publication of WO2023115123A1 publication Critical patent/WO2023115123A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/32—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by aldehydo- or ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to a crystalline intermediate useful in the manufacture of 6,7- epoxytigliane compounds.
  • Methods of making the 6,7-epoxytigliane compounds using the crystalline intermediates are also disclosed as well as high purity 6,7-epoxytigliane compounds that are able to be produced using the crystalline intermediate.
  • 6,7-Epoxytiglianes are a class of diterpene esters that have been shown to have human and veterinary therapeutic application in diseases such as solid tumour cancers and bacterial infections as well as in promoting wound healing (W02007070985, WO2014169356).
  • a number of 6,7-epoxytigliane compounds are naturally occurring in plants belonging to Fontainea and Hylandia species, for example tigilanol tiglate (compound 1, 12-tigloyl-13-(2- methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-l-tigliaen-3-one, W02007070985).
  • epoxytigliane compounds are derived from naturally occurring 6,7-epoxytigliane compounds by a semi-synthetic process, for example 12,13-dihexanoyl-6,7-epoxy- 4,5,9,12,13,20-hexahydroxy-l-tigliaen-3-one (compound 2, WO2014169356).
  • the extracts obtained contain multiple closely related epoxytigliane compounds that can be difficult to separate. Since variation in the 6,7-epoxytigliane compounds extracted occurs in the ester groups at the C12 and C13 positions of the 6,7-epoxytigliane structure, it has previously been proposed that the extract be treated to de-acylate the C12 and C13 esters to provide a single 6,7-epoxytigliane compound bearing hydroxy groups at the C12 and C13 positions. This intermediate compound may then be synthetically manipulated to produce a single desired natural or non-natural 6,7-epoxytigliane compound (WO2014169356).
  • 6,7-epoxytigliane compounds produced in this manner still require purification to ensure the removal of undesirable solvents and impurities that may be considered toxic.
  • Some synthetic processes have been found to result in a small portion of the 6,7 epoxytigliane compound undergoing ring opening of the 6,7-epoxide ring to form hydrochloride adducts such as:
  • the present invention is based at least in part on the discovery that a key intermediate in the synthetic preparation of therapeutically useful 6,7-epoxytigliane compounds crystallizes to form a high purity product and allows the preparation of the desired 6,7-epoxytigliane compounds in high yield and high purity.
  • a crystalline form of a compound of formula (I) comprising the steps of: i) providing a composition comprising one or more compounds of formula (II): wherein each R is independently selected from H and -C(O)Ri, wherein when only one compound of formula(II) is present in the composition, at least one R group is not hydrogen; and
  • Ri is selected from Ci-C2oalkyl, C2-C2oalkenyl, C2-C2oalkynyl, cycloalkyl, aryl, Ci- walkylcycloalkyl; C2-ioalkenylcycloalkyl, C2-ioalkynylcycloalkyl, Ci-ioalkylaryl, C2- walkenylaryl, C2-ioalkynylaryl, Ci-ioalkylC(0)R2, C2-ioalkenylC(0)R2, C2- ioalkynylC(0)R 2 , Ci-ioalkylCH(OR2)(OR 2 ), C(0)C2-ioalkenylCH(OR2)(OR 2 ), C2-ioalkynylCH(OR2)(OR2), Ci-ioalkylSR2, C2-ioalkenylSR2, C2-ioalkynylSR2, Ci- ioalkenylC(0)OR 2 , C2-ioal
  • R2 is hydrogen, -Ci-ioalkyl, -C2-ioalkenyl, -C2-ioalkynyl, cycloalkyl or aryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl or aryl group is optionally substituted; ii) forming a 5,20-acetonide of formula (III): by treating the compound of formula (II) with 2,2-dimethoxypropane and a weakly acidic catalyst; iii) de-esterifying the esters at C12 and C13 of formula (III) to provide a compound of formula (I): by treating the compound of formula (III) with a base; and iv) crystallizing the compound of formula (I).
  • Figure 1 provides a representation of the X-ray powder diffraction pattern of anhydrous crystalline Form A of a compound of formula (la).
  • Figure 2 provides a representation of the X-ray powder diffraction pattern of the anhydrous crystalline Form B of a compound of formula (la).
  • Figure 3 provides a representation of the X-ray powder diffraction pattern of the methanol solvate of the compound of formula (la).
  • Figure 4 provides a representation of the X-ray powder diffraction pattern of the dihydrate of the compound of formula (la).
  • an element means one element or more than one element.
  • the term “about” refers to a quantity, level, value, dimension, size, or amount that varies by as much as 30%, 25%, 20%, 15% or 10% to a reference quantity, level, value, dimension, size, or amount.
  • the term “about” include peaks within ⁇ 0.2 degrees 29 of the stated position, especially ⁇ 0.1 degrees 29 of the stated position.
  • an XRPD peak at “about 10.0 degrees 29” means that the stated peak occurs from 9.8 to 10.2 degrees 29.
  • alkyl refers to optionally substituted linear and branched saturated hydrocarbon groups having 1 to 20 carbon atoms. Where appropriate, the alkyl group may have a specified number of carbon atoms, for example, -Ci-Ce alkyl which includes alkyl groups having 1, 2, 3, 4, 5 or 6 carbon atoms in linear or branched arrangements.
  • Non-limiting examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, 5- and /-butyl, pentyl, 2-methylbutyl, 3 -methylbutyl, hexyl, 2-m ethylpentyl, 3 -methylpentyl, 4-m ethylpentyl, 2-ethylbutyl, 3 -ethylbutyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl and pentadecyl.
  • alkenyl refers to optionally substituted, unsaturated linear or branched hydrocarbons, having 2 to 20 carbon atoms and having at least one double bond. Where appropriate, the alkenyl group may have a specified number of carbon atoms, for example, C2- Ce alkenyl which includes alkenyl groups having 2, 3, 4, 5 or 6 carbon atoms in linear or branched arrangements.
  • Non-limiting examples of alkenyl groups include, ethenyl, propenyl, isopropenyl, butenyl, 5- and /-butenyl, pentenyl, hexenyl, hept-l,3-diene, hex- 1,3 -diene, non- 1,3,5-triene and the like.
  • alkynyl refers to optionally substituted unsaturated linear or branched hydrocarbons, having 2 to 20 carbon atoms, having at least one triple bond.
  • the alkynyl group may have a specified number of carbon atoms, for example, C2-C6 alkynyl which includes alkynyl groups having 2, 3, 4, 5 or 6 carbon atoms in linear or branched arrangements.
  • Non-limiting examples include ethynyl, propynyl, butynyl, pentynyl and hexynyl.
  • cycloalkyl and “carbocyclic” refer to optionally substituted saturated or unsaturated, but not aromatic, mono-cyclic, bicyclic or tricyclic hydrocarbon groups.
  • the cycloalkyl group may have a specified number of carbon atoms, for example, C3-C6 cycloalkyl is a carbocyclic group having 3, 4, 5 or 6 carbon atoms.
  • Non-limiting examples may include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl and the like.
  • Aryl means a Ce-Cu membered monocyclic, bicyclic or tricyclic carbocyclic ring system having up to 7 atoms in each ring, wherein at least one ring is aromatic.
  • aryl groups include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl and biphenyl.
  • the aryl may comprise 1-3 benzene rings. If two or more aromatic rings are present, then the rings may be fused together, so that adjacent rings share a common bond.
  • substituents include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, ec-butyl, tert-butyl, vinyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, methylthio, ethylthio, propylthio, isopropylthio, butylthio, hydroxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, fluoro, chloro, bromo, iodo, cyano, nitro, -CO2H, -CO2CH3, -C(O)CH3, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, difluoromethyl, difluoromethoxy, difluoromethylthio, morpholino, amino, methylamino, dimethylamino, phenyl, phenoxy, phenyl carbonyl
  • the epoxytigliane compounds may be in the form of pharmaceutically acceptable salts. It will be appreciated however that non-pharmaceutically acceptable salts also fall within the scope of the invention since these may be useful as intermediates in the preparation of pharmaceutically acceptable salts or may be useful during storage or transport.
  • Suitable pharmaceutically acceptable salts include, but are not limited to, salts of pharmaceutically acceptable inorganic acids such as hydrochloric, sulphuric, phosphoric, nitric, carbonic, boric, sulfamic, and hydrobromic acids, or salts of pharmaceutically acceptable organic acids such as acetic, propionic, butyric, tartaric, maleic, hydroxymaleic, fumaric, maleic, citric, lactic, mucic, gluconic, benzoic, succinic, oxalic, phenylacetic, methanesulphonic, toluenesulphonic, benezenesulphonic, salicyclic sulphanilic, aspartic, glutamic, edetic, stearic, palmitic, oleic, lauric, pantothenic, tannic, ascorbic and valeric acids.
  • pharmaceutically acceptable inorganic acids such as hydrochloric, sulphuric, phosphoric, ni
  • Base salts include, but are not limited to, those formed with pharmaceutically acceptable cations, such as sodium, potassium, lithium, calcium, magnesium, ammonium and alkylammonium.
  • Basic nitrogen-containing groups may be quarternized with such agents as lower alkyl halide, such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl and diethyl sulfate; and others.
  • the epoxytigliane compounds may possess asymmetric centres and are therefore capable of existing in more than one stereoisomeric form.
  • the invention thus also relates to compounds are substantially one stereoismeric form at one or more asymmetric centres e.g., greater than about 90% ee, such as about 95% or 97% ee or greater than 99% ee, as well as mixtures, including racemic mixtures, thereof.
  • Such stereoisomers may be obtained by isolation from natural sources, by asymmetric synthesis, for example using chiral intermediates, or by chiral resolution.
  • the compounds of the invention may also exist as geometrical isomers.
  • the invention also relates to compounds in substantially pure cis (Z) or trans (E) forms or mixtures thereof.
  • 6,7-epoxytigliane compound refers to a compound having the following basic carbon cyclic structure:
  • the compounds have a tricyclo[9.3.0.0]tetradecane system with a fused cyclopropane ring appended to the six membered ring.
  • the epoxide is fused to the seven-membered ring in the 6,7-position.
  • 6,7-epoxytigliane compound is an 6,7-epoxytiglien-3-one compound.
  • epoxytiglien-3-one compound refers to a compound having an epoxytigliane structure defined above where the five-membered ring has a l,2-ene-3-one structure:
  • substantially pure form refers to a product having greater than 96% chemical purity, especially greater than 97%, greater than 98%, greater than 99% or 100% chemical purity and/or greater than 97% ee, especially greater than 98% or greater than 99% ee and more especially 100% ee.
  • substantially pure form refers to where impurity compounds A and/or B are present in less than 0.5%, less than 0.1%, less than 0.05% and most especially they are absent.
  • the present invention relates to a compound of formula (I) in crystalline form, especially a compound of formula (la) in crystalline form:
  • the crystalline form is an anhydrous crystalline form. In other embodiments, the crystalline form is a methanol solvate. In another embodiment, the crystalline form is a dihydrate.
  • the crystalline form may be one of two forms.
  • Form A of the anhydrous crystalline form exhibits an X-ray powder diffraction (XRPD) pattern comprising at least one peak at about 10.5 degrees 29.
  • XRPD X-ray powder diffraction
  • anhydrous crystalline Form A exhibits an XRPD pattern comprising a peak at about 10.5 degrees 29 and at least one peak selected from the group consisting of about 6.2 and about 7.6 degrees 29.
  • the anhydrous crystalline Form A exhibits an XRPD pattern comprising a peak at about 10.5 degrees 29, at least one peak selected from about 6.2 and about 7.6 degrees 29 and at least one peak selected from about 12.5 and about 15.2 degrees 29.
  • the anhydrous crystalline Form A exhibits an XRPD pattern comprising a peak at about 10.5 degrees 29, at least one peak selected from about 6.2 and about 7.6 degrees 29, at least one peak selected from about 12.5 and about 15.2 degrees 29 and at least one peak selected from about 16.2, about 16.7, about 18.3, about 19.9, about 23.3 and about 27. 8 degrees 29.
  • the XRPD pattern is substantially the same as Figure 1.
  • the anhydrous crystalline Form A has an XRPD pattern with peaks at 6.2, 7.6, 10.5, 12.5, 15.2, 16.2, 16.7, 18.3, 19.9, 21.5, 23.3, 25.2 and 27.8 ⁇ 0.2 degrees 29.
  • anhydrous crystalline Form A is characterized by a Fourier Transform Infrared (FTIR) spectrum in the 4000 - 550 cm' 1 spectral range in attenuated total reflectance (ATR) mode comprising absorption frequencies at about 3458.4, 3345.6, 3056.9, 2984.6, 2968.6, 2941.1, 2882.4, 1708.3, 1636.1, 1458.5, 1376.1, 1319.0, 1223.5, 1085.7, 1025.4, 1000.3, 973.7, 930.3, 902.1, 880.3, 832.1 and 769.0 cm' 1 .
  • FTIR Fourier Transform Infrared
  • the anhydrous crystalline Form A has a water content of less than 0.5%, especially less than 0.3%, for example about 0.28%.
  • the anhydrous crystalline Form A has a level of residual organic solvent of less than 50 ppm, especially less than 40 ppm and more especially less than 25 ppm, for example, about 34 ppm.
  • a second anhydrous crystalline form may be formed from anhydrous crystalline Form A under high humidity conditions, for example, a temperature of 25°C and a relative humidity of 80% over 68 hours.
  • Anhydrous crystalline Form B is stable upon storage and may be present upon storage of anhydrous crystalline Form A.
  • Form B of the anhydrous crystalline form exhibits an X-ray powder diffraction (XRPD) pattern comprising at least one peak at about 11.4 degrees 29.
  • XRPD X-ray powder diffraction
  • anhydrous crystalline Form B exhibits an XRPD pattern comprising a peak at about 11.4 degrees 29 and at least one peak selected from the group consisting of about 8.5 and about 9.8 degrees 29.
  • the anhydrous crystalline Form B exhibits an XRPD pattern comprising a peak at about 11.4 degrees 29, at least one peak selected from about 8.5 and about 9.8 degrees 29 and at least one peak selected from about 4.9 and about 14.6 degrees 29.
  • the anhydrous crystalline Form B exhibits an XRPD pattern comprising a peak at about 11.4 degrees 29, at least one peak selected from about 8.5 and about 9.8 degrees 29, at least one peak selected from about 4.9 and about 14.6 degrees 29 and at least one peak selected from about 16.5, about 17.5, about 19.5, about 21.4, about 27.7 and about 28.7 degrees 29.
  • the XRPD pattern is substantially the same as Figure 2.
  • the anhydrous crystalline Form B has an XRPD pattern with peaks at 4.9, 8.5, 9.8, 11.4, 14.6, 16.5, 17.5, 19.5, 21.4, 27.7, 28.7 ⁇ 9.2 degrees 29.
  • the anhydrous crystalline Form B has a water content of less than 9.5%, especially less than 9.3%, for example about 9.28%. In some embodiments, the anhydrous crystalline Form B has a level of residual organic solvent of less than 50 ppm, especially less than 40 ppm and more especially less than 25 ppm, for example, about 34 ppm.
  • the crystalline form exhibits an X-ray powder diffraction (XRPD) pattern comprising at least one peak at about 9.5 degrees 29.
  • XRPD X-ray powder diffraction
  • the crystalline form exhibits an XRPD pattern comprising a peak at about 9.5 degrees 29 and at least one peak selected from the group consisting of about 7.2 and about 13.1 degrees 29.
  • the crystalline form exhibits an XRPD pattern comprising a peak at about 9.5 degrees 29, at least one peak selected from about 7.2 and about 13.1 degrees 29 and at least one peak selected from about 11.5, about 14.5 and about 17.9 degrees 29.
  • the crystalline form exhibits an XRPD pattern comprising a peak at about 9.5 degrees 29, at least one peak selected from about 7.2 and about 13.1 degrees 29, at least one peak selected from about 11.5, about 14.5 and about 17.9 degrees 29 and at least one peak selected from about 29.3, about 21.2, about 22.8 and about 32.6 degrees 29.
  • the XRPD pattern is substantially the same as Figure 3.
  • the methanol solvate crystalline form has an XRPD pattern with peaks at 7.2, 9.5, 11.5, 12.6, 13.1, 14.9, 14.5, 17.9, 17.7, 17.9, 19.2, 29.3, 21.2, 22.8, 23.7, 24.7, 27.1, 28.3, 29.7 and 32.6 ⁇ 9.2 degrees 29.
  • the crystalline methanol solvate is characterised by a Fourier Transform Infra-red (FTIR) spectrum in the 4999 - 559 cm' 1 spectral range in attenuated total reflectance (ATR) mode comprising absorption frequencies at about 3443.1, 3374.1, 3189.1, 3992.6, 2975.7, 2944.4, 2863.6, 1793.3, 1635.7, 1461.9, 1372.9, 1299.7, 1221.1, 1977.1, 1925.1, 992.9, 973.9, 929.7, 995.8, 876.7, 829.9 and 769.1.
  • FTIR Fourier Transform Infra-red
  • the crystalline methanol solvate has a differential scanning calorimetry (DSC) profile characterised by an endothermic peak having an onset at about 145.33 °C and in some embodiments one or two less intense endothermic peaks at about 221.12 °C and /or 234.22 °C.
  • DSC differential scanning calorimetry
  • the crystalline methanol solvate comprises 4 to 8%, especially 5 to 6% residual methanol as determined by thermogravimetric analysis.
  • the crystalline form is a dihydrate crystalline form of a compound of formula (la)
  • the crystalline form exhibits an X-ray powder diffraction (XRPD) pattern comprising at least one peak at about 10.5 degrees 29.
  • the crystalline form exhibits an XRPD pattern comprising a peak at about 10.5 degrees 29 and at least one peak selected from the group consisting of about 7.4 and about 12.4 degrees 29.
  • the crystalline form exhibits an XRPD pattern comprising a peak at about 10.5 degrees 29, at least one peak selected from about 7.4 and about 12.4 degrees 29 and at least one peak selected from about 6.2, about 9.9 and about 15.3 degrees 29.
  • the crystalline form exhibits an XRPD pattern comprising a peak at about 10.5 degrees 29, at least one peak selected from about 7.4 and about 12.4 degrees 29, at least one peak selected from about 6.2, about 9.9 and about 15.3 degrees 29 and at least one peak selected from about 8.9, about 18.6, about 20.2, about 22.4, about 22.9, about 26.0, about 27.0, about 27.3 and about 33.7 degrees 29.
  • the XRPD pattern is substantially the same as Figure 4.
  • the dihydrate crystalline form has an XRPD pattern with peaks at 6.2, 7.4, 8.9, 9.9, 10.5, 12.4, 15.3, 18.6, 20.2, 21.1, 22.4, 22.9, 26.0, 27.0, 27.3 and 33.7 ⁇ 0.2 degrees 29.
  • the dihydrate crystalline form may be formed upon storage at low temperature, such as about 5°C, and may be converted back to anhydrous Form A or anhydrous Form B by storage at room temperature and 80% humidity.
  • the crystalline form is substantially pure, for example, having greater than 96%, 97%, 98% or 99% chemical purity, especially between 99% and 100% chemical purity, more especially between 99.5% and 100% chemical purity and optionally greater than 97% ee, especially greater than 98% ee or greater than 99% ee and more especially 100% ee.
  • the crystalline form is a single crystalline form, for example, Form A or Form B of the anhydrous crystalline form.
  • the crystalline form is a mixture of crystalline forms, for example, a mixture of Form A and Form B or a mixture of From A and the dihydrate crystalline solvate.
  • the compound of formula (la) may still be substantially pure having greater than 96%, 97%, 98% or 99% chemical purity, especially between 99% and 199% chemical purity, more especially between 99.5% and 199% chemical purity and optionally greater than 97% ee, especially greater than 98% ee or greater than 99% ee and more especially 199% ee.
  • the crystalline form of the compound of formula (I) is an anhydrous crystalline form, especially the anhydrous crystalline form of the compound of formula (la):
  • the anhydrous crystalline form is Form A. In other embodiments, the anhydrous crystalline form is Form B.
  • the crystalline forms of the invention may be prepared by crystallization of a compound of formula (I) from a suitable solvent. Suitable solvents were investigated as shown in Example 7.
  • Crystallization from methanol provided the crystalline methanol solvate. Crystallization occurred after dissolution of the compound in methanol, suitably 2 to 10 volumes (2 V to 10 V) compared to the weight of compound, especially 3 V to 8 V, more especially 3 V to 7V and more especially about 3 V to 6V at 20 to 25°C. Crystallization occurred spontaneously after dissolution.
  • Crystallization from acetonitrile provided the crystalline anhydrous form, Form A, via a 1 : 1 acetonitrile (MeCN) solvate.
  • Dissolution of the compound of formula (I) was obtained at reflux, with crystallization occurring upon cooling to about 68 to 70°C. Crystallization occurred in ratios of 3 V to 15V of solvent compared to the weight of compound, especially 4V to 12V and more especially 5V to 10V.
  • the initial MeCN solvate was collected by filtration and upon drying yielded the anhydrous crystalline Form A.
  • anhydrous crystalline form, Form A was free of solvents and provided higher yields, 85-95% yield, compared to the crystalline methanol solvate, 70-80% yield.
  • anhydrous crystalline Form A was stable at 60% relative humidity, at higher humidity, such as 80% relative humidity was able to transform to a dihydrate (storage at about 5°C) or a second anhydrous crystalline form, Form B, (storage at about 25°C).
  • Fontainea picrosperma mixture of epoxytigliane compounds in one aspect of the present invention there is provided a method of making a crystalline form of a compound of formula (I) comprising the steps of: i) providing a composition comprising one or more compounds of formula (II): wherein each R is independently selected from H and -C(O)Ri, wherein when only one compound of formula (II) is present in the composition, at least one R group is not hydrogen; and
  • Ri is selected from Ci-C2oalkyl, C2-C2oalkenyl, C2-C2oalkynyl, cycloalkyl, aryl, Ci- oalkylcycloalkyl; C2-ioalkenylcycloalkyl, C2-ioalkynylcycloalkyl, Ci-ioalkylaryl, C2- walkenylaryl, C2-ioalkynylaryl, Ci-ioalkylC(0)R2, C2-ioalkenylC(0)R2, C2- ioalkynylC(0)R 2 , Ci-ioalkylCH(OR2)(OR 2 ), C(0)C2-ioalkenylCH(OR2)(OR 2 ), C2-ioalkynylCH(OR2)(OR2), Ci-ioalkylSR2, C2-ioalkenylSR2, C2-ioalkynylSR2, Ci- ioalkylC(0)OR 2 , C2-io
  • C2-1 oalkynyl R2 is hydrogen, -Ci-ioalkyl, -C2-ioalkenyl, -C2-ioalkynyl, cycloalkyl or aryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl or aryl group is optionally substituted; ii) forming a 5,20-acetonide of formula (III): by treating the compound of formula (II) with 2,2-dimethoxypropane and a weakly acidic catalyst; iii) de-esterifying the esters at C12 and C13 of formula (III) to provide a compound of formula (I): by treating the compound of formula (III) with a base; and crystallizing the compound of formula (I).
  • composition comprising one or more compounds of formula (II) comprises a mixture of compounds of formula (II), especially a mixture of compounds of formula (Ila):
  • composition comprising one or more compounds of formula (II) or (Ila) comprises one or more compounds selected from the following: or a stereoisomer thereof, especially a stereoisomer having stereocentres as shown in formula (Ila).
  • the weakly acidic catalyst is for example, a weak Bronsted acid catalyst such as pyridinium p-toluene sulfonic acid, or camphorsulfonic acid (CSA), a cation exchange resin, p-toluene sulfonic acid, H2SO4, zinc chloride and other Lewis acids, and BF3 etherate.
  • a weak Bronsted acid catalyst such as pyridinium p-toluene sulfonic acid, or camphorsulfonic acid (CSA), a cation exchange resin, p-toluene sulfonic acid, H2SO4, zinc chloride and other Lewis acids, and BF3 etherate.
  • the weakly acidic catalyst is pyridinium p-toluene sulfonic acid.
  • the solvent used in the formation of the acetonide is any suitable solvent that is able to solubilise the reactants. Suitable solvents include acetone, dimethyl formamide, toluene, dichloromethane, tetrahydrofuran (THF), 2-methyltetrahydrofuran and acetonitrile.
  • Suitable bases include carbonates such as CS2CO3, Na2CCh, K2CO3 and Li2CO3.
  • DMF dimethylformamide
  • the 5,20-acetonide compound of formula (I) is purified by column chromatography before crystallization. In other embodiments, the compound of formula (I) is crystallized without chromatographic purification.
  • Crystallization of the compound of formula (I) may be from a suitable solvent such as methanol or acetonitrile. From methanol solvents, the methanol solvate crystalline form was provided. From acetonitrile, the crystalline acetonitrile solvate, crystalline anhydrous forms, Form A and Form B and the dihydrate crystalline form were provided. In particular embodiments, the crystalline forms are crystalline forms of the compound of formula (la).
  • One or more crystalline forms of the compound of formula (I) may be used to prepare 6.7- epoxytigliane compounds of therapeutic value, such as compound 1 and compound 2, in high yield and high purity.
  • Use of the one or more crystalline forms of the compound of formula (I) in the synthesis of compounds of 6,7-epoxytigliane compounds may improve the overall yield obtained by up to 50% and/or may reduce impurities, such as solvents and/or hydrochloride adducts A and B, to therapeutically acceptable levels.
  • the method of the invention further comprises the step of esterifying one or both of the C 12 and C13 hydroxy groups of the compound of formula (I) as shown in scheme 2 where the starting material is the crystalline compound of formula (I): activated carboxylic acid Scheme 2
  • each R3 is the same.
  • the C12 and C13 hydroxy groups are esterified in separate sequential reactions to produce a 6,7-epoxytigliane compound having different C12 an C13 esters where each R3 is different.
  • the first esterification occurs at the C13 hydroxy group and the reaction may be monitored to ascertain when reaction at C13 is complete.
  • the carboxylic acid may be activated for reaction with the hydroxy group by any means known in the art.
  • the activated carboxylic acid is an acid chloride or an anhydride.
  • the activated carboxylic acid may be a symmetric anhydride such as tiglic anhydride.
  • the activated carboxylic acid may be an unsymmetrical anhydride, for example, tiglic-pivalic anhydride.
  • the carboxylic acid is activated with a carbodiimide
  • suitable carbodiimides include N,N’ -di cyclohexylcarbodiimide (DCC), N,N’ -diisopropylcarbodiimide (DIC) or l-ethyl-3-(3- dimethylaminopropyl)carbodiimide (EDC) and the like.
  • Each R3 is the same or different and is independently selected from the group consisting of H and -C(O)Ri and Ri is selected from Ci-C2oalkyl, C2-C2oalkenyl, C2-C2oalkynyl, cycloalkyl, aryl, Ci-ioalkylcycloalkyl; C2-ioalkenylcycloalkyl, C2-ioalkynylcycloalkyl, Ci-ioalkylaryl, C2- walkenylaryl, C2-ioalkynylaryl, Ci-ioalkylC(0)R2, C2-ioalkenylC(0)R2, C2-ioalkynylC(0)R2, Ci-ioalkylCH(OR2)(OR 2 ), C(0)C2-ioalkenylCH(OR2)(OR 2 ), C2-ioalkynylCH(OR2)(OR 2 ), Ci- ioalkylSR2, C2-ioalkenylSR2, C
  • R2 is hydrogen, -Ci-ioalkyl, -C2-ioalkenyl, -C2-ioalkynyl, cycloalkyl or aryl; wherein each alkyl, alkenyl, alkynyl, cycloalkyl or aryl group is optionally substituted.
  • at least one of R3 is other than hydrogen, especially where both R3 are other than hydrogen.
  • the 5,20-acetonide protecting group may be removed to form the epoxytigliane compound of formula (IV) as shown in Scheme 3 :
  • the acetonide protecting group may be removed under any suitable conditions as known in the art, for example, aqueous acidic conditions.
  • suitable acids that may be used to provide the acidic conditions include hydrochloric acid (HC1), trifluoroacetic acid, perchloric acid, sulfuric acid, AmberliteTM resin or other strong ion exchange resins and Lewis acids such as BF3 etherate.
  • Suitable solvents include aqueous and alcoholic solvents such as water, methanol, aqueous methanol, aqueous tetrahydrofuran, aqueous acetonitrile and the like.
  • suitable conditions include HC1 in aqueous methanol or aqueous tetrahydrofuran, trifluoroacetic acid in aqueous acetonitrile or aqueous perchloric acid (HCIO4).
  • the method produces 12,13-dihexanoyl-6,7-epoxy-4,5,9,12,13,20- hexahydroxy-l-tigliaen-3-one (compound 2) in high yield and/or in substantially pure form.
  • the method produces 12-tigloyl-13-(2-methylbutanoyl)-6,7-epoxy- 4,5,9,12,13,20-hexahydroxy-l-tigliaen-3-one (compound 1) in high yield and/or substantially pure form.
  • the flow rate was 1. mL/min, injection volume 5.0 pL, column temperature 40 °C and detection at 249 nm.
  • the crude concentrated methanolic solution from Example 1 was extracted twice with n-hexane (30 L for the 1 st extraction, 15 L for the 2 nd extraction) at room temperature. Each extraction was mixed for about 10 minutes and then the phases allowed to separate for 10 minutes before the hexane phase was collected. The collected hexanic phases were combined and re-extracted twice with a methanol/water (90/10) mixture and then discharged. The combined hydromethanolic phase was pooled with the previous methanol extractions and was diluted with 10% NaCl (aq, 5L). The aqueous methanolic solution was extracted three times with di chloromethane (10 L for the 1 st extraction, 5 for the 2 nd and 3 rd extractions). The combined organic phases were dried over Na2SO4 and then concentrated under vacuum at a temperature of less than 40°C until an oil having less than 0.1% water content as measured by KF was obtained.
  • a further batch of purified crude extract was prepared using the above-described process except that the combined hydromethanolic phase with pooled with previous methanol extractions and diluted with water rather than 10% NaCl, in order to reduce chloroadduct formation.
  • Example 3 Preparation of Epoxytigliane-5,20 acetonide esters
  • the oil from Example 2 was dissolved in acetone (4 L); then, 2,2-dimethoxypropane (1.125 L) and pyridinium p-toluenesulfonate (0.338 Kg) were added. The mixture was heated under stirring at 40°C for 25 hours. A sample was then checked by HPLC analysis as described in Example 1 to confirm the completion of the reaction. Ethyl acetate was added to the reaction mixture and the reaction mixture was then washed twice with water. The collected organic phases were dried under vacuum to yield the 5,20-acetonide esters as an oil.
  • Example 3 The oil from Example 3 was dissolved in methanol (10L) and 1 kg of CS2CO3 was added. The mixture was maintained under stirring at 25°C for 22 hours, after which water (2L) was added. The resulting mixture was washed three times with n-hexane (3 x 3L). Ethyl acetate (10 L), water (8L) and H2SO4 2 N solution (5L) were added to the residual hydro-methanolic phases. The organic phase was collected and the hydro-methanolic solution was re-extracted with ethyl acetate (10 L x 4 times), pooling together all the ethyl acetate organic solutions. The ethyl acetate solution was then washed twice with 10% Na2SO4 aq.
  • a further batch of 12,13-dihexanoyl-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-l-tigliaen-3-one- 5,20-acetonide was prepared using the above-described process except that, prior to addition of H2SO4, a preliminary water washing step was carried out, to reduce chloroadduct formation.
  • the pooled fractions were diluted with water and extracted three times with dichloromethane.
  • a further batch of 12,13-dihexanoyl-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-l-tigliaen-3-one (compound 2) was prepared using the above-described process except that, prior to final concentration to dryness of 12,13-dihexanoyl-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-l- tigliaen-3-one, a water-washing step is carried out on concentrated 12,13-dihexanoyl-6,7- epoxy-4,5,9,12,13,20-hexahydroxy-l-tigliaen-3-one to prevent formation of an impurity.
  • Example 7 Crystallization Study Early intermediates in the synthetic pathway for producing compound 2, such as the compound of formula (I), were investigated for crystallization potential.
  • Example 8 Crystalline compound (la) as MeOH solvate
  • a sample of the product of Example 4 (amorphous solid, with HPLC purity of about 80 - 85% was dissolved in methanol at room temperature; complete dissolution occurred in a few seconds. Crystallization was triggered without control immediately after dissolution. The product obtained was a solvate crystalline form with a MeOH content around 5-6%.
  • Table 3 the crystallization trials carried out are summarized:
  • Crystalline methanol solvate of Compound of formula (la) was characterized by an X-ray powder diffraction (X-RPD) pattern obtained using the copper wavelengths i and I2 of 1.54056 A and 1.54439 A showing a crystalline structure and comprising distinctive reflections, expressed as 29 degrees values, at 7.2, 9.5, 11.5, 12.6, 13.1, 14.0, 14.5, 17.0, 17.7, 17.9, 19.2, 20.3, 21.2, 22.8, 23.7, 24.7, 27.1, 28.3, 29.7, 32.6 29.
  • X-RPD X-ray powder diffraction
  • the Fourier-Transform InfraRed Spectroscopy (FTIR) spectrum for the crystalline methanol solvate in the 4000-500 cm' 1 spectral range in ATR mode comprised characteristic absorption frequencies at approximately 3443.1, 3374.1, 3189.1, 3002.6, 2975.7, 2944.4, 2863.6, 1703.3, 1635.7, 1461.9, 1372.9, 1290.7, 1221.1, 1077.1, 1025.1, 992.0, 973.9, 929.7, 905.8, 876.7, 829.0, 769.1 cm' 1 .
  • a Differential Scanning Calorimetry (DSC) profile of the crystalline methanol solvate is characterized by an endothermic peak with onset at aboutl45.33°C and two other less intense endothermic peaks with onset at about 221.12°C and 234.22°C, respectively.
  • the crystalline methanol solvate is further characterised by a Thermogravimetric profile (TG) showing a weight loss of 5.5 %, which is consistent with the presence of 5-6% of residual MeOH.
  • TG Thermogravimetric profile
  • Example 9 Anhydrous crystalline Compound of formula (la) A mixture of the product of Example 4 and acetonitrile was stirred under reflux until a clear solution was obtained; then the solution was allowed to cool where crystallization spontaneously occurred upon cooling at about 68 to 70 °C.
  • Table the crystallization trials carried out are summarized:
  • the MeCN solvate was characterized by an X-ray powder diffraction (X-RPD) pattern obtained using the copper wavelengths i and I2 of 1.54056 A and 1.54439 A showing a crystalline structure and comprising distinctive reflections, expressed as 29 degrees values, at 6.2, 7.5, 10.4, 12.2, 14.9, 16.0, 17.7, 18.5, 19.5, 20.9, 22.4, 24.7, 26.8 and 33.4 degrees 29 ⁇ 0.2 29.
  • X-RPD X-ray powder diffraction
  • Form A of a crystalline anhydrous Compound of formula (la) was characterized by an X-ray powder diffraction (X-RPD) pattern obtained using the copper wavelengths i and I2 of 1.54056 A and 1.54439 A showing a crystalline structure and comprising distinctive reflections, expressed as 29 degrees values, at 6.2, 7.6, 10.5, 12.5, 15.2, 16.2, 16.7, 18.3, 19.9,
  • X-RPD X-ray powder diffraction
  • Form A of the anhydrous crystalline Compound of formula (la) was further characterized by a water content of about 0.28% by Coulometric Titration and residual organic solvent determination of 34 ppm by Head Space Gas Chromatography with flame ionization detection (HS GC FID).
  • Form A of the crystalline anhydrous Compound of formula (la) was stable for at least 9 months in industrial packaging (Type III amber glass vial (10 mL) closed by a black plastic screw cap with polyethylene stoppers) at 25°C and 60% relative humidity and as a free crystalline powder at 80°C and 60% humidity for 24 hours.
  • Form A of the anhydrous crystalline compound Upon storage at 5°C for 5 days Form A of the anhydrous crystalline compound was transformed into a dihydrate form of the compound having a Loss on Drying (LoD) of 9.3% wt. The dihydrate form could be transformed back to Form A of the anhydrous crystalline form upon storage at 25°C and 89% relative humidity for 5 days.
  • LoD Loss on Drying
  • the dihydrate crystalline form was characterized by an X-ray powder diffraction (X-RPD) pattern obtained using the copper wavelengths i and I2 of 1.54956 A and 1.54439 A showing a crystalline structure and comprising distinctive reflections, expressed as 29 degrees values, at 6.2, 7.4, 8.9, 9.9, 19.5, 12.4, 15.3, 18.6, 29.2, 21.1, 22.4, 22.9, 26.9, 27.9, 27.3 and 33.7 ⁇ 9.2 degrees 29.
  • X-RPD X-ray powder diffraction
  • Form B Upon storage of the Form A anhydrous crystalline form at 25°C at 89% relative humidity for 68 hours, or 49°C at 89% relative humidity for 7 days, a new stable anhydrous crystalline form was formed, Form B.
  • Form B had a LoD of 9.3% wt and was stable at 25°C at 89% relative humidity for at least a further 7 days unchanged.
  • the anhydrous crystalline Form B was characterized by an X-ray powder diffraction (X-RPD) pattern obtained using the copper wavelengths i and I2 of 1.54956 A and 1.54439 A showing a crystalline structure and comprising distinctive reflections, expressed as 29 degrees values, at 4.9, 8.5, 9.8, 11.4, 14.6,
  • Example 10 Comparison with and without purification by crystallization With the process described above for the preparation of Compound 2, analysis was performed to compare the preparation of Compound 2 via the compound of formula (la) with and without crystallization.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un intermédiaire cristallin utile dans la fabrication de composés 6,7-époxytigliane. L'invention concerne également des procédés de fabrication des composés 6,7-époxytigliane à l'aide des intermédiaires cristallins, ainsi que des composés 6,7-époxytigliane de haute pureté qui peuvent être produits à l'aide de l'intermédiaire cristallin.
PCT/AU2022/051546 2021-12-21 2022-12-21 Intermédiaires cristallins WO2023115123A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2021904153A AU2021904153A0 (en) 2021-12-21 Crystalline Intermediates
AU2021904153 2021-12-21

Publications (1)

Publication Number Publication Date
WO2023115123A1 true WO2023115123A1 (fr) 2023-06-29

Family

ID=86900792

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2022/051546 WO2023115123A1 (fr) 2021-12-21 2022-12-21 Intermédiaires cristallins

Country Status (1)

Country Link
WO (1) WO2023115123A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070985A1 (fr) * 2005-12-23 2007-06-28 Qbiotics Limited Derives de tiglien-3-one
WO2014169356A1 (fr) * 2013-04-18 2014-10-23 Qbiotics Limited Procédés et compositions pour la cicatrisation de plaies
WO2018018097A1 (fr) * 2016-07-28 2018-02-01 Qbiotics Limited Méthode de traitement de tumeurs.
WO2018170559A1 (fr) * 2017-03-23 2018-09-27 Qbiotics Limited Traitement d'association pour le traitement ou la prévention de tumeurs
WO2020206504A1 (fr) * 2019-04-12 2020-10-15 QBiotics Pty Ltd Procédé de traitement de tumeurs
WO2020252535A1 (fr) * 2019-06-19 2020-12-24 QBiotics Pty Ltd Perturbation de biofilm
WO2022019251A1 (fr) * 2020-07-20 2022-01-27 陽吉 小川 Dispositif de génération de champ magnétique, système de génération de champ magnétique, procédé de production d'objet cible irradié, objet cible irradié, liquide, eau, humidificateur, procédé d'humidification, programme et support de stockage lisible par ordinateur

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070985A1 (fr) * 2005-12-23 2007-06-28 Qbiotics Limited Derives de tiglien-3-one
WO2014169356A1 (fr) * 2013-04-18 2014-10-23 Qbiotics Limited Procédés et compositions pour la cicatrisation de plaies
WO2018018097A1 (fr) * 2016-07-28 2018-02-01 Qbiotics Limited Méthode de traitement de tumeurs.
WO2018170559A1 (fr) * 2017-03-23 2018-09-27 Qbiotics Limited Traitement d'association pour le traitement ou la prévention de tumeurs
WO2020206504A1 (fr) * 2019-04-12 2020-10-15 QBiotics Pty Ltd Procédé de traitement de tumeurs
WO2020252535A1 (fr) * 2019-06-19 2020-12-24 QBiotics Pty Ltd Perturbation de biofilm
WO2022019251A1 (fr) * 2020-07-20 2022-01-27 陽吉 小川 Dispositif de génération de champ magnétique, système de génération de champ magnétique, procédé de production d'objet cible irradié, objet cible irradié, liquide, eau, humidificateur, procédé d'humidification, programme et support de stockage lisible par ordinateur

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GLEN M. BOYLE ET AL: "Intra-Lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models", PLOS ONE, vol. 9, no. 10, pages e108887, XP055460453, DOI: 10.1371/journal.pone.0108887 *

Similar Documents

Publication Publication Date Title
CA2818225C (fr) Procedes de preparation d'everolimus et d'intermediaires de celui-ci
SU776557A3 (ru) Способ получени оптически активных антрациклинонов
JP2017039742A (ja) 結晶性ミノサイクリン塩基及びその製造方法
JP2009132735A (ja) 新規なセファロタキサン誘導体の製造に用いられるカルボン酸誘導体
EP2100894A1 (fr) Pyridopyrimidinones utilisés comme inhibiteurs de la kinase de type Plk1 (polo-like kinase)
AU785385B2 (en) Novel derivatives and analogues of galanthamin
EP3169692A1 (fr) Nouvelle forme de sofosbuvir et sa méthode de préparation
US20110009480A1 (en) Biologically active taxane analogs and methods of treatment
AU2004296191B2 (en) Vinca derivatives
AU2003290075B2 (en) Method for production of the r,r (or s,s) configuration of glycopyrronium stereoisomers
WO2023115123A1 (fr) Intermédiaires cristallins
AU2014339222B2 (en) A crystalline anhydrous form of Cabazitaxel, process for the preparation and pharmaceutical compositions thereof
US11566000B2 (en) Crystalline form of sofpironium bromide and preparation method thereof
EP3842438B1 (fr) Procédé de préparation de composé d'ectéinascidine et d'un intermédiaire de celui-ci
JP2016534066A (ja) カバジタキセルの結晶性溶媒和物形態
ES2462756T3 (es) Procedimientos de síntesis de alcaloides opiáceos con formación reducida de impurezas
RU2423992C1 (ru) Способ получения пакистанамина и берберина хлорида из berberis sibirica
Thirumalai Rajan et al. Novel Crystalline Polymorph Of Baloxavir Marboxil And Process For Preparation Thereof
KR20020093090A (ko) (5Ｒ)-(메틸아미노)-5,6-디히드로-4Ｈ-이미다조[4,5,1-ｉｊ]퀴놀린-2(1Ｈ)-티온
JP5863846B2 (ja) イリノテカンの製造方法
CN116098910A (zh) 一种用于治疗脑水肿的化合物
WO2024084517A1 (fr) 3-phényl-3-(aryloxy) propan-1-amines et leur procédé de préparation
Sh et al. Synthesis of Tetrahydroisoquinolines Based on Homoveratrilamine and 3–Indolylacetic Acid
Sangeetha et al. Synthesis of 12, 13-dihydro-5-oxoquinolino [2, 3-a] carbazoles, 3, 11-dihydro-2, 4-dioxopyrano [2, 3-a] carbazoles and quinolino [2, 3-b] carbazolo [6, 5-a] pyran-7, 8-diones
HU185305B (en) Process for preparing vincine and apovincine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22908885

Country of ref document: EP

Kind code of ref document: A1